Chikungunya Virus Associated Central Nervous System Disease Characterized
By LabMedica International staff writers Posted on 09 Dec 2015 |
Chikungunya virus (CHIKV) is a re-emerging alphavirus with the most common symptoms of the infection are fever and joint pain and most people recover within a week, though for some people the joint pain can continue for months and even years.
Recently, Asian lineage CHIKV emerged in the Caribbean and expanded to the Americas, and recent clinical and experimental data indicate differences in the pathogenicity between Asian and American lineages. The major outbreaks that have occurred since 2005 in the Indian Ocean islands were attributable to a new Indian Ocean lineage that evolved from the East Central South African (ECSA) lineage.
Scientists at the Central University Hospital in Saint Pierre (Reunion Island) and their colleagues carried out an ambispective cohort study aimed at characterizing clinical and biological features of CHIKV-associated central nervous system (CNS) disease, disease burden, and 3-year neurologic outcome of patients with this condition. All patients hospitalized between September 1, 2005, and June 30, 2006, with CHIKV infection and neurologic symptoms that led to lumbar puncture (LP) eligible for the study.
Patients with positive cerebral spinal fluid (CSF) for CHIKV ribonucleic acid (RNA) or anti-CHIKV immunoglobulin M (IgM) were studied further. Anti-CHIKV IgM assay in the CSF was performed by enzyme-linked immunosorbent assay (ELISA) using the ETIMAX 3000 (DiaSorin; Saluggia, Italy). A one-step TaqMan real-time quantitative polymerase chain reaction (PCR) was performed from CSF samples using the Light LightCycler 2.0 system (Roche Diagnostics; Basel, Switzerland).
Among the 129 CHIKV-infected patients with CNS disease, biological analysis of the CSF was positive for 55 CHIKV RNA or 30 anti-CHIKV IgM in 78 patients and negative in 51 patients. A total of 24 people had encephalitis that was associated with chikungunya virus, for a cumulative incidence rate of 8.6/100,000 people. Encephalitis was more likely to occur in infants and people aged older than 65 years. The incidence rate in infants was 187/100,000 people and it was 37/100,000 people in those aged older than 65. The death rate for those with chikungunya virus-associated encephalitis was 17%. An estimated 30% to 45% of the infected persons with encephalitis had persisting disabilities. The disabilities included behavioral changes and problems with thinking and memory skills in infants, and post-infectious dementia in previously healthy adults.
Patrick Gérardin, MD, the lead author of the study said, “Since there is no vaccine to prevent chikungunya and no medicine to treat it, people who are traveling to these areas should be aware of this infection and take steps to avoid mosquito bites, such as wearing repellent and long-sleeves and pants if possible. These numbers are both much higher than the rates of encephalitis in the USA in these age categories, even when you add together all the causes of encephalitis. The consequences of this encephalitis seem to be particularly harmful in newborns.” The study was published on November 25, 2015, in the journal Neurology.
Related Links:
Central University Hospital in Saint Pierre
DiaSorin
Roche Diagnostics
Recently, Asian lineage CHIKV emerged in the Caribbean and expanded to the Americas, and recent clinical and experimental data indicate differences in the pathogenicity between Asian and American lineages. The major outbreaks that have occurred since 2005 in the Indian Ocean islands were attributable to a new Indian Ocean lineage that evolved from the East Central South African (ECSA) lineage.
Scientists at the Central University Hospital in Saint Pierre (Reunion Island) and their colleagues carried out an ambispective cohort study aimed at characterizing clinical and biological features of CHIKV-associated central nervous system (CNS) disease, disease burden, and 3-year neurologic outcome of patients with this condition. All patients hospitalized between September 1, 2005, and June 30, 2006, with CHIKV infection and neurologic symptoms that led to lumbar puncture (LP) eligible for the study.
Patients with positive cerebral spinal fluid (CSF) for CHIKV ribonucleic acid (RNA) or anti-CHIKV immunoglobulin M (IgM) were studied further. Anti-CHIKV IgM assay in the CSF was performed by enzyme-linked immunosorbent assay (ELISA) using the ETIMAX 3000 (DiaSorin; Saluggia, Italy). A one-step TaqMan real-time quantitative polymerase chain reaction (PCR) was performed from CSF samples using the Light LightCycler 2.0 system (Roche Diagnostics; Basel, Switzerland).
Among the 129 CHIKV-infected patients with CNS disease, biological analysis of the CSF was positive for 55 CHIKV RNA or 30 anti-CHIKV IgM in 78 patients and negative in 51 patients. A total of 24 people had encephalitis that was associated with chikungunya virus, for a cumulative incidence rate of 8.6/100,000 people. Encephalitis was more likely to occur in infants and people aged older than 65 years. The incidence rate in infants was 187/100,000 people and it was 37/100,000 people in those aged older than 65. The death rate for those with chikungunya virus-associated encephalitis was 17%. An estimated 30% to 45% of the infected persons with encephalitis had persisting disabilities. The disabilities included behavioral changes and problems with thinking and memory skills in infants, and post-infectious dementia in previously healthy adults.
Patrick Gérardin, MD, the lead author of the study said, “Since there is no vaccine to prevent chikungunya and no medicine to treat it, people who are traveling to these areas should be aware of this infection and take steps to avoid mosquito bites, such as wearing repellent and long-sleeves and pants if possible. These numbers are both much higher than the rates of encephalitis in the USA in these age categories, even when you add together all the causes of encephalitis. The consequences of this encephalitis seem to be particularly harmful in newborns.” The study was published on November 25, 2015, in the journal Neurology.
Related Links:
Central University Hospital in Saint Pierre
DiaSorin
Roche Diagnostics
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Microbiology News
- Integrated Solution Ushers New Era of Automated Tuberculosis Testing
- Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia